Find and Pitch Jounalists, Get Your Story Covered

Tags: Daily, Events, Health Services, Health Tech, Hospitals Hospitals hospital-administration Finances finance

	Profile	Recent Articles on Subject
1	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics	With uncertainty roiling Big Pharma, execs are placing lower-risk bets - 26 days ago By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years - about 2 months ago Will 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A? - about 2 months ago How pharma was instrumental in President Jimmy Carter’s global health efforts - about 2 months ago Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in - 4 months ago Big Pharma earnings hang hope on the next generation of blockbusters - 4 months ago Why pharma megamergers may become a relic of the past - 4 months ago Top pharma and biotech conferences 2025 - 5 months ago Market share shakeup: Big Pharma’s bestselling drugs drive industry shifts in 2024’s first half - 7 months ago Has pharma emerged from the ‘age of uncertainty’? - 8 months ago AstraZeneca’s $80B sales goal by 2030 reflects industry’s penchant for long-term bets - 9 months ago How pharma’s surging M&A is impacting the industry’s tech sector - 11 months ago Who’s getting left behind in the weight loss bonanza? - 11 months ago How to make 2024 a banner year for biopharma, despite the headwinds - about 1 year ago Pharma’s financial market will be a tale of two cities in 2024 - about 1 year ago Biopharma’s FTC headache deepens with guideline shifts years in the making - about 1 year ago The thorniest questions facing pharma, according to a leading bioethicist - over 1 year ago How Big Pharma keeps the oncology engines hot with a host of strategies - over 1 year ago The PharmaVoice 100: Rare disease warriors - over 1 year ago
2	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Pharma’s forecast for 2025: Sowing seeds of a rebound - about 1 month ago Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking - about 2 months ago The ability to pivot will be ‘key’ as pharma’s tariff threat looms - about 2 months ago 3 closely watched drugs that failed in the clinic - 3 months ago Pharma takes aim at a wily foe — the Epstein-Barr virus - 4 months ago 2024 PharmaVoice 100s: Rare Disease Warriors - 4 months ago 2024 PharmaVoice 100s: Trailblazers - 5 months ago Why pharma should redefine ‘women’s health’ - 6 months ago What 3 layoff stories reveal about pharma’s troubles - 6 months ago Pharma’s ‘it’ therapy — a new drug class gaining steam - 6 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 9 months ago Where competition is heating up in pharma - 9 months ago Could Novo, Lilly become first trillion-dollar healthcare companies? - about 1 year ago The biggest questions hanging over pharma in 2024 - about 1 year ago Pharma execs sound off on trends and policies they’re tracking in 2024 - about 1 year ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - about 1 year ago 10 of our most read articles in 2023 - about 1 year ago 3 standout digital innovations in pharma this year - over 1 year ago A startling drop in U.S. life expectancy — and how pharma could help turn the tide - over 1 year ago PharmaVoice 100s: Entrepreneurs - over 1 year ago PharmaVoice 100s: Clinical trial gurus - over 1 year ago
3	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Biopharma in 2025: Outlook for Obesity Meds, Drug Prices, Regulation & More - about 2 months ago
4	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about a Merck deal for an obesity pill, a departing FDA official, and more - 3 months ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - 4 months ago STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 6 months ago STAT+: Pharmalittle: We’re reading about Europe’s pharma reform, weight-loss meds, and more - 12 months ago STAT+: Pharmalittle: We’re reading about a pharma job slowdown, diet drugs boosting GDP, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about weight loss drugs, a cell therapy for melanoma, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about Medicaid and sickle cell, pharma CEOs, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - about 1 year ago STAT+: Pharmalittle: Employers hire virtual providers as obesity drug gatekeepers; Vertex non-opioid nerve pain drug succeeds in mid-stage trial - about 1 year ago STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer - over 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - over 1 year ago STAT+: Pharmalittle: Weight-loss drugs fuel boom for firms that fill syringes; employers that cover obesity drug may double in 2024 - over 1 year ago
5	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Big Pharma’s new DTC play: partnering with digital health providers - 3 months ago Oncology, obesity and more: Where pharma R&D is headed in 2025 - 3 months ago From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies - 4 months ago As election day nears, Trump and Harris veer in different directions on pharma - 5 months ago M&A is ready to explode, and that’s good news for pharma layoffs - 7 months ago As the GLP-1 market booms, other healthcare companies are cashing in - 8 months ago
6	Emily Mullin Wired Staff writer at WIRED. Covers biotechnology. Fall 2021 fellow. Pittsburgh, Pennsylvania biotechnology	RFK Plans to Take on Big Pharma. It’s Easier Said Than Done - 3 months ago
7	Mohana Ravindranath STAT News Health tech reporter at STAT. Oakland, CA + Washington, D.C. Health techreporting	Pfizer, Eli Lilly execs push back as senators scrutinize drugmakers’ telehealth moves - 3 months ago
8	N. Adam Brown MD MedPage Today Healthcare Strategist/Communicator. Washington, D.C. Healthcarestrategycommunication	Direct-to-Consumer Drugs: Big Pharma's Digital Health Play - 6 months ago
9	Rebecca Pifer Healthcare Dive Reporter @healthcaredive. New York City, United States insurancedigital health	Large employers forecast 7.8% hike in health costs next year, thanks to rising pharmacy spend - 6 months ago
10	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Is pharma still fearful of the Inflation Reduction Act? - 7 months ago

Journalists covering health medical pharma